Elotuzumab

Drug Profile

Elotuzumab

Alternative Names: BMS-901608; Empliciti; HuLuc63; PDL063

Latest Information Update: 15 Jul 2017

Price : $50

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD319 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma

Most Recent Events

  • 24 Jun 2017 Efficacy and adverse events data from a phase III trial in Multiple myeloma released by Bristol-Myers Squibb
  • 06 Jun 2017 Interim efficacy and adverse events data from a phase II trial in Multiple Myeloma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Updated interim efficacy and adverse events data from the ELOQUENT-2 phase III trial in Multiple Myeloma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top